Leal Therapeutics Inc.
- Address
- 17 Briden Street Office 329
Sponsor Overview
Specializations
Neuromuscular Disease
Leal Therapeutics Inc. focuses its clinical research on amyotrophic lateral sclerosis, with attention to disease areas affecting motor neuron function and progressive muscle weakness. Its trial activity is centered on adult participants living with ALS.
- Amyotrophic lateral sclerosis
- Motor neuron disease
- Neuromuscular impairment
The sponsor’s research activity in this area is directed toward identifying treatments relevant to the neurological decline associated with ALS.
Central Nervous System Therapeutics
The company’s clinical program includes investigation of therapies administered through the spinal canal, reflecting interest in treatments that act within the central nervous system. This area is closely tied to neurological disorders requiring targeted delivery to the cerebrospinal fluid.
- Intrathecal administration
- Spinal canal delivery
- Cerebrospinal fluid targeting
Research in this domain supports therapeutic development for conditions where direct access to the central nervous system is important.
Safety and Tolerability Research
Leal Therapeutics Inc. is engaged in clinical evaluation of the safety and tolerability of investigational therapy in adults with ALS. The sponsor’s current clinical focus includes monitoring treatment-related effects in a neurological population.
- Safety assessment
- Tolerability evaluation
- Adult ALS population
This area is relevant to the development of therapies intended for chronic neurodegenerative disease management.
Investigational Neurotherapies
The sponsor’s pipeline activity includes work on LTX-002, an investigational therapy being studied in amyotrophic lateral sclerosis. The research reflects interest in novel approaches for neurological disease intervention and symptom-related disease modification.
- LTX-002
- Investigational therapy
- Neurological intervention
Clinical work in this area is directed toward advancing treatment options for neurodegenerative disorders.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis |  Germany Italy Sweden The Netherlands | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 5 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
5 centres- Address
- Via Cherasco 15, 10126 Turin
- Address
- Via Giacomo Venezian 1, 20133 Milan
- Address
- Eugeniavagen 3, 171 64 Solna
- Address
- Arnold-Heller-Strasse 3, Brunswik, 24105 Kiel
- Address
- Heidelberglaan 100, 3584 CX Utrecht
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Leal Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.